|Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy|
PE Sax, C Tierney, AC Collier, MA Fischl, K Mollan, L Peeples, C Godfrey, ...
New England Journal of Medicine 361 (23), 2230-2240, 2009
|Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1|
Annals of internal medicine 155 (6), 402, 2011
|Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data|
KR Mollan, M Smurzynski, JJ Eron, ES Daar, TB Campbell, PE Sax, ...
Annals of internal medicine 161 (1), 1-10, 2014
|Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results|
PE Sax, C Tierney, AC Collier, ES Daar, K Mollan, C Budhathoki, ...
Journal of Infectious Diseases 204 (8), 1191-1201, 2011
|Crowdsourcing HIV test promotion videos: a noninferiority randomized controlled trial in China|
W Tang, L Han, J Best, Y Zhang, K Mollan, J Kim, F Liu, M Hudgens, ...
Clinical infectious diseases 62 (11), 1436-1442, 2016
|Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes|
TJ Wilkin, JE McKinnon, AG DiRienzo, K Mollan, CV Fletcher, ...
The Journal of infectious diseases 199 (6), 866-871, 2009
|Crowdsourcing to expand HIV testing among men who have sex with men in China: a closed cohort stepped wedge cluster randomized controlled trial|
W Tang, C Wei, B Cao, D Wu, KT Li, H Lu, W Ma, D Kang, H Li, M Liao, ...
PLoS medicine 15 (8), e1002645, 2018
|The differential short-and long-term effects of HIV-1 latency-reversing agents on T cell function|
G Clutton, Y Xu, PL Baldoni, KR Mollan, J Kirchherr, W Newhard, K Cox, ...
Scientific reports 6 (1), 1-17, 2016
|Generalizing evidence from randomized trials using inverse probability of sampling weights|
AL Buchanan, MG Hudgens, SR Cole, KR Mollan, PE Sax, ES Daar, ...
Journal of the Royal Statistical Society. Series A,(Statistics in Society …, 2018
|ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patients|
17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) San …, 2010
|Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention|
MR Nicol, Y Fedoriw, M Mathews, HMA Prince, KB Patterson, E Geller, ...
The Journal of Clinical Pharmacology 54 (5), 574-583, 2014
|A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and …|
WC Miller, IF Hoffman, BS Hanscom, TV Ha, K Dumchev, Z Djoerban, ...
The Lancet 392 (10149), 747-759, 2018
|Ultra-long-acting removable drug delivery system for HIV treatment and prevention|
M Kovarova, SR Benhabbour, I Massud, RA Spagnuolo, B Skinner, ...
Nature communications 9 (1), 1-11, 2018
|Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine|
KY Smith, C Tierney, K Mollan, CS Venuto, C Budhathoki, Q Ma, ...
Clinical infectious diseases 58 (4), 555-563, 2014
|Disclosure of sexual orientation to health professionals in China: results from an online cross‐sectional study|
W Tang, J Mao, S Tang, C Liu, K Mollan, B Cao, T Wong, Y Zhang, ...
Journal of the International AIDS Society 20 (1), 21416, 2017
|Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection|
CB Jabara, F Hu, KR Mollan, SE Williford, P Menezes, Y Yang, JJ Eron, ...
Antimicrobial agents and chemotherapy 58 (10), 6079-6092, 2014
|Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202|
HJ Ribaudo, ES Daar, C Tierney, GD Morse, K Mollan, PE Sax, MA Fischl, ...
The Journal of infectious diseases 207 (3), 420-425, 2013
|Benefits and potential harms of HIV self-testing among men who have sex with men in China: an implementation perspective|
Y Qin, W Tang, A Nowacki, K Mollan, SA Reifeis, MG Hudgens, NS Wong, ...
Sexually transmitted diseases 44 (4), 233, 2017
|Race/ethnicity and the pharmacogenetics of reported suicidality with efavirenz among clinical trials participants|
KR Mollan, C Tierney, JN Hellwege, JJ Eron, MG Hudgens, RM Gulick, ...
The Journal of infectious diseases 216 (5), 554-564, 2017
|Balancing trained immunity with persistent immune activation and the risk of simian immunodeficiency virus infection in infant macaques vaccinated with attenuated Mycobacterium …|
K Jensen, MG dela Pena-Ponce, M Piatak, R Shoemaker, K Oswald, ...
Clinical and Vaccine Immunology 24 (1), 2017